Clinic
Citywide Urgent Care NJ LLC
Citywide Urgent Care NJ LLC was paid $1.52M by Medicaid between Aug 2021 and Nov 2024, across 26 billing codes. Its largest line is S9083, Global fee urgent care centers — 16% of everything it billed.
33Billing provider infoCITYWIDE URGENT CARE NJ LLC
BLOOMFIELD, NJ 07003
BLOOMFIELD, NJ 07003
33aNPI1689259822assigned 03/09/2021
33bProvider typeUrgent Care Clinic/Center
28Total paid$1.52M
24GClaims33,333
24DCodes billed26
24AFirst – last monthAug 2021 – Nov 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in New Jersey
Rank by total paid#16 of 60
Median peer was paid$255K
This provider vs. median6.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 4,131 | $199K | |
| 2022 | 13,633 | $687K | |
| 2023 | 9,697 | $362K | |
| 2024incomplete | 5,872 | $272K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| S9083 | Global fee urgent care centers | 16% | 2,462 | 2,021 | $245K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 2,972 | 2,620 | $205K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 11% | 1,743 | 1,522 | $173K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 2,745 | 2,400 | $170K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 11% | 2,779 | 2,478 | $169K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 8.8% | 2,128 | 2,025 | $133K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.9% | 1,978 | 1,588 | $120K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.3% | 1,397 | 1,237 | $95K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 6.1% | 6,096 | 5,042 | $93K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 2.4% | 620 | 469 | $36K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.0% | 351 | 250 | $30K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 461 | 373 | $18K |
14 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,328 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,720 | $10K |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | <1% | 18 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 124 | $1K |
| 81025 | <1% | 557 | $845.04 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 110 | $695.00 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 73 | $351.90 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 111 | $350.00 |
| 99051 | <1% | 1,933 | $314.14 | |
| 90686 | <1% | 14 | $94.37 | |
| 86580 | <1% | 31 | $52.00 | |
| 81000 | <1% | 555 | $33.92 | |
| 81002 | <1% | 15 | $8.00 | |
| 90674 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGETZ, MORDECHAI (ADMINISTRATOR)